Rein Therapeutics Inc.
RNTX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $1,681 | $4,292 | $3,054 | $3,322 |
| G&A Expenses | $0 | $2,579 | $2,555 | $0 |
| SG&A Expenses | $3,811 | $2,579 | $2,555 | $2,475 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $5,492 | $6,871 | $5,609 | $5,797 |
| Operating Income | -$5,492 | -$6,871 | -$5,609 | -$5,797 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | -$89 | $49 | $108 | -$36,728 |
| Pre-Tax Income | -$5,581 | -$6,822 | -$5,501 | -$42,525 |
| Tax Expense | $0 | $0 | $0 | -$1,544 |
| Net Income | -$5,581 | -$6,822 | -$5,501 | -$40,981 |
| % Margin | – | – | – | – |
| EPS | -0.21 | -0.28 | -2,510.05 | -1.89 |
| % Growth | 25% | 100% | -132,706.9% | – |
| EPS Diluted | -0.21 | -0.28 | -2,510.05 | -1.89 |
| Weighted Avg Shares Out | 26,361 | 24,188 | 2 | 22 |
| Weighted Avg Shares Out Dil | 26,361 | 24,188 | 2 | 22 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $1 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $1 | $0 | $0 |
| EBITDA | -$5,581 | -$6,870 | -$5,609 | -$42,525 |
| % Margin | – | – | – | – |